CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: A meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 12, 2012, Pages 1574-1581

  Deng, R ^a,b   Yang, T ^c   Wang, Y ^a   Tang, Naping ^a,d  

^a National Shanghai Center for New Drug Safety Evaluation and Research   (China)

^b Department of General Toxicology   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

Author keywords

Antituberculosis drug induced liver injury; CYP2E1 RsaI PstI polymorphism; Meta analysis

Indexed keywords

CYTOCHROME P450 2E1; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; BRAZILIAN; CAUCASIAN; CHINESE; CONTROLLED STUDY; CYP2E1 GENE; DNA POLYMORPHISM; DRUG EFFICACY; ETHNIC GROUP; FEMALE; GENE; GENOTYPE; HUMAN; INDIA; JAPANESE; KOREAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ACETYLATION; ADULT; AGED; ANTITUBERCULAR AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP2E1; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84870315244     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0304     Document Type: Review

References (42)

1. World Organization Health. Global tuberculosis control. WHO report 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
3. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
4. Nathwani R A, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006; 10: 207-217.
5. Thompson N P, Caplin M E, Hamilton M I, et al. Antituberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384-1388.
6. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
7. Pande J N, Singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from anti-tuberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
8. Lorent N, Sebatunzi O, Mukeshimana G, Van den Ende J, Clerinx J. Incidence and risk factors of serious adverse events during anti-tuberculous treatment in Rwanda: a prospective cohort study. PLoS ONE 2011; 6: e19566.
9. Sharma S K, Balamurugan A, Saha P K, Pandey R M, Mehra N K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919.
10. Yew W W, Leung C C. Anti-tuberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
11. Knowles S R, Uetrecht J, Shear N H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587-1591.
12. Leung L, Kalgutkar A S, Obach R S. Metabolic activation in drug-induced liver injury. Drug Metab Rev 2012; 44: 18-33.
13. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8: 839-851.
14. Nelson S D, Mitchell J R, Timbrell J A, Snodgrass W R, Corcoran G B III. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976; 193: 901-903.
15. Kölble K. Regional mapping of short tandem repeats on human chromosome 10: cytochrome P450 gene CYP2E, D10S196, D10S220 and D10S225. Genomics 1993; 18: 702-704.
16. Lucas D, Ménez C, Girre C, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5: 298-304.
17. Neafsey P, Ginsberg G, Hattis D, Johns D O, Guyton K Z, Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 2009; 12: 362-388.
18. Little J, Bradley L, Bray M S, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002; 156: 300-310.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
21. Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Brit Med J 1997; 315: 629-634.
23. Ren X F, Xu J M. [Clinical analysis and long-term follow-up of cases with acute drug-induced liver injury and clinical study on gene polymorphism of CYP2E1]. MD thesis. Hefei, China: Anhui Medical University, 2008. [Chinese]
24. Bose P D, Sarma M P, Medhi S, Das B C, Husain S A, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in anti-tuberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26: 312-318.
25. Wang T, Wang W. [Relationship between cytochrome P450-2E1 polymorphisms and the susceptibility to anti-tuberculosis drug-induced hepatitis]. MD thesis. Beijing, China: Chinese People's Liberation Army General Hospital, Chinese PLA Postgraduate Medical School, 2006. [Chinese]
26. Wang T, Wang W, Wang Z Y, Pan Y Y, Su Q Q, He L X. Association of P450-2E1 and GSTM1 genetic polymorphisms with susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Chin J Tuberc Respir Dis 2009; 32: 585-587.
27. Wang T, Yu H T, Wang W, Pan Y Y, He L X, Wang Z Y. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with anti-tuberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. J Int Med Res 2010; 38: 977-986.
28. Huang Y S, Chern H D, Su W J, et al. Cytochrome P450 2E1 genotype and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
29. Lee S-W, Chung L S-C, Huang H-H, Chuang T-Y, Liou Y-H, Wu L S-H. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14: 622-626.
30. Tang S W, Lv X Z, Zhang Y, et al. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. J Clin Pharm Ther 2012; 37: 588-593.
31. An H R, Wu U Q, Wang Z Y, Zhang J X, Liang Y. NAT 2 and CYP2E1 polymorphisms associated with anti-tuberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 2012; 39: 535-543.
32. Cho H J, Koh W J, Ryu Y J, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with anti-tuberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87: 551-556.
33. Kim S H, Kim S H, Bahn J W, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10: 1767-1779.
34. Roy B, Ghosh S K, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of anti-tuberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol 2006; 21: 784-786.
35. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 2011; 25: 803-812.
36. Teixeira R L, Morato R G, Cabello P H, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of anti-tuberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106: 716-724.
37. Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R, Constenla L, Fernández-Villar A. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2010; 11: 1205-1206.
38. Vuilleumier N, Rossier M F, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62: 423-429.
39. Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10: 1433-1445.
40. Mitchell J R, Zimmerman H J, Ishak K G, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84: 181-192.
41. Ryan D E, Ramanathan L, Iida S, et al. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 1985; 260: 6385-6393.
42. Stephens E A, Taylor J A, Kaplan N, et al. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185-192.